Biogen (BIIB) stock gains as Piper Sandler upgrades the company, citing positives in the company’s recent deal to acquire eye ...

In other words, this healthcare stock looks risky right now and is, at this point, unlikely to make investors rich over the ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always ...

But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. Everyone has their own methods for finding great value opportunities, but our model ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biogen (BIIB) and Nkarta (NKTX). According to TipRanks.com, Zemansky is a 5-star analyst with an ...

The company's asset-to-be has two commercialized medicines on the market based on the same active ingredient.

Piper Sandler now forecasts Biogen’s revenue to grow to over $10.5 billion by 2027, with improving profitability and ...

Biogen: recent performance snapshot Biogen (BIIB) has been on investors’ radar after a mixed stretch in the stock, with a slight negative move over the past month but a positive total return over the ...

Cambridge, Massachusetts-based Biogen Inc. (BIIB) is a biotechnology company that discovers, develops, and delivers innovative therapies for serious neurological and neurodegenerative diseases. It is ...

Healthcare company Biogen (BIIB 2.82%) wasn't looking very healthy on the stock market on Monday. Investors traded out of its ...

Biogen has forged a settlement with investors who claimed the company misled them in describing how it gained a controversial ...